A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition.
WATFORD, UK. February 2nd, 2026 – IBSA UK&I has today announced the launch of Perovial®, the first licensed hyaluronic acid injectable indicated for the management of Peyronie’s disease (PD) in its acute phase.
Perovial® offers healthcare professionals a new, evidence-based option for men presenting with early symptoms of Peyronie’s disease, helping to address long-standing gaps in treatment.
PD is a chronic, progressive condition characterised by penile curvature, deformity, pain and erectile dysfunction, resulting from plaque formation within the tunica albuginea[1,2,3]. Estimates suggest it affects between 0.3% and 13.1% of men worldwide4, yet the true prevalence is likely higher due to underdiagnosis, embarrassment and delayed presentation5. Around 60% of men experience a negative impact on quality of life with Peyronie’s disease[5], while treatment options during the acute phase remain limited and variable within clinical pathways.[5]
Early recognition is essential. During the acute phase, when inflammatory activity and symptom progression are most active, intervention may help limit scarring and deformity[5]. However, awareness of Peyronie’s disease is somewhat limited, potentially contributing to delayed treatment of the condition.
A new injectable pathway for acute phase management
Perovial® is delivered via intrapenile injection over a 10–12-week treatment course6. The hyaluronic acid formulation with its antioxidative and antifibrotic properties is designed to soften plaque and support tissue remodelling, helping to slow or limit the progression of scarring[6].
Clinical studies report improvements in penile curvature, plaque size and erectile function, with favourable patient satisfaction and a tolerable safety profile[7,8,9].
As the first hyaluronic acid injectable licensed for Peyronie’s disease in the UK, Perovial® provides clinicians with a clear, accessible and structured intervention option ahead of chronic-stage surgical pathways. It also offers an alternative to other potential treatments with variable evidence bases, supporting a more consistent standard of care for patients.
Professor David Ralph, Professor of Urology, University College London, St Peter’s Andrology, and a UK urology Andrologist said: “Peyronie’s disease is often misunderstood, underdiagnosed and undertreated, partly because many men delay seeking help and partly because clinicians have had limited options to offer during the acute phase. The availability of a licensed hyaluronic acid injectable such as Perovial® provides a much-needed structured pathway for early intervention. Improving recognition of the acute phase and providing accessible treatment choices which could make a significant difference to long-term outcomes for many patients.”
Kevin, a patient living with Peyronie’s disease said: “Peyronie’s disease quietly crept into every part of my life and put real pressure on my relationship. I didn’t talk about it because I genuinely didn’t know where to turn, and that silence was incredibly isolating. Looking back, if I’d understood that the early signs needed prompt attention, I would have acted much sooner. Knowing there’s now a licensed treatment available in the early stages means men don’t have to sit in silence or wait until things worsen.”
ENDS